Delivery Order SPE2DB24D3014-SPE2DB25FKUPE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $2,740.40 with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of ProQuad vials valued at $5,426.92, with an ultimate completion date of August 14, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award was made through open competition with no...
- The Defense Logistics Agency (DLA) awarded a $6,469.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $3,308.68 to AmerisourceBergen Drug Corp for ProQuad vials on August 25, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,140.38 to AmerisourceBergen Drug Corp for ProQuad vials on August 11, 2025, with a completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order supports federal medical procurement needs and is being performed at the contractor's facility in Conshohocken, Pennsylvania. ProQuad is a combination vaccine providing immunity against measles, mumps, rubella, and varicella, making this order...
- The Defense Logistics Agency (DLA) awarded a $1,687.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 19, 2025, with a completion date of September 10, 2025. This non-set-aside competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,670.90 to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.9 million through December 2026. ProQuad is a combination vaccine used to protect...
- The Defense Logistics Agency awarded a $5,480.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUPEDelivery Order
The Defense Logistics Agency awarded a $10,853.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 25, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The award was made competitively without set-aside designation to the Conshohocken, Pennsylvania-based pharmaceutical distributor, one of the federal government's major medical supply vendors. ProQuad is a combination vaccine used for immunization against measles, mumps, rubella, and varicella, making this delivery order part of DLA's broader pharmaceutical and vaccine supply mission supporting military healthcare programs and other federal medical systems. As a critical vendor in the federal medical procurement ecosystem, AmerisourceBergen fulfills delivery orders across the company's extensive portfolio of pharmaceutical products, medical devices, and vaccines through its comprehensive global pharmaceutical support vehicle, enabling efficient distribution of essential medical commodities to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 9/4/25 |